Speedy Molecular Diagnostics for Rapid Testing
They are responsible for compatibility testing of microfluidic chips and implementing quality control systems for large-scale manufacturing of In Vitro Diagnostic (IVD) chips. GENSPEED Biotech is ISO 13485 and ISO 9001 certified, specializing in the development, production, and distribution of rapid tests. Their technology platform, GENSPEED, is used for rapid detection of pathogens in periodontitis, nosocomial infections, and COVID-19. They have extensive expertise in DNA/RNA/Protein-microarray technology for detecting microorganisms and various biomarkers from clinical samples. Their team has also developed a microfluidic chip-based test system using chemiluminescence signal detection and passively driven microfluidics, with a strong background in microbiology, molecular biology, biochemistry, and biophysics.
Projects involved in
Biosensors for Food Safety & Public Health Monitoring
Development of a versatile lab-on-a-cartridge platform for rapid, multiplexed detection of pathogens like SARS-CoV-2 and Influenza, as well as contaminants in food. This innovative technology aims to enhance public health monitoring and ensure food safety through scalable and cost-effective diagnostics.
Shedding Light on Von Willebrand Disease: Technoclone's Pioneering Diagnostic Solution
In the intricate realm of blood disorders, Von Willebrand Disease (VWD) emerges as a prevalent yet often misunderstood condition. With Technoclone's latest initiative, the landscape of VWD diagnostics is on the brink of transformation, promising a future of enhanced accuracy, speed, and accessibility in patient care.
Advancing Patient Triage with ViroGates' Multiplex Inflammatory Biomarker Detection
ViroGates, an international in vitro diagnostics company based in Denmark, is renowned for its innovative solutions in emergency medicine. Their suPARnostic® product line, used extensively in emergency departments, enhances clinical decisions regarding the hospitalization or discharge of acute medical patients.
Advancing Chronic Kidney Disease Diagnostics - Hycult Biotech's Complement Biomarker Assay
Hycult Biotech, together with the Microfluidics Innovation Hub, is developing a rapid, non-invasive multiplex assay for detecting complement activation markers in chronic kidney disease. This advanced microfluidic platform aims to improve early diagnosis and monitoring, offering a reliable alternative to invasive kidney biopsies
Contact us today and together we will evaluate which manufacturing process best suits your microfluidic needs!
Are you ready to scale-up?
Contact us to discuss your microfluidic project requirements and objectives.
Consultation
Partner Match
We connect you with the right manufacturing experts from our network.
We oversee the entire project, ensuring smooth coordination and timely delivery